Adjuvant Therapy with Pembrolizumab in Renal Cell Carcinoma: Real-World Experiences from a Retrospective, Multi-Institutional Cohort
Urologia Internationalis · 24.12.2024 · 109 (3) · 291-298
DOI: 10.1159/000543278 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Urologia Internationalis, online erschienen am 24.12.2024. Verfasst von Angelika Mattigk und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology and Paediatric Urology, University Hospital Ulm, Ulm, Germany. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Abstract (Originalsprache)
Introduction
Adjuvant pembrolizumab versus placebo significantly improved disease-free survival (DFS) in renal cell carcinoma (RCC) patients at high risk (HR) of recurrence following nephrectomy in KEYNOTE-564 trial (NCT03142334). The objective of this study was to evaluate efficacy and safety of adjuvant pembrolizumab in a real-world setting.
Methods
In this multicenter retrospective study, RCC patients receiving adjuvant pembrolizumab between 01/22 and 10/23 at seven tertiary referral centers were included. DFS and treatment safety were assessed.
Results
Fifty-two patients with RCC were included. 24 (46%), 5 (9.6%), 22 (42%), and 1 (1.9%) patients were classified as intermediate to high risk (IR to HR), HR, M1 with no evidence of disease (M1NED), and unknown. At a median follow-up of 6 months, DFS rates at 6 months were 64.2% in the overall cohort. In subgroup analyses, M1NED patients demonstrated significantly lower DFS compared to non-metastatic (combined: IR to HR/HR) patients (log-rank: p = 0.025). Regarding toxicity, grade 3 or higher adverse events occurred in 26% of patients. Treatment discontinuations were reported in 20% of the patients.
Conclusion
Recurrence rates in the M1NED group remained high and occurred earlier in our real-world compared to KEYNOTE-564. Long-term toxicities were comparable to clinical trials data.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology and Paediatric Urology, University Hospital Ulm, Ulm, Germany.
- Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany.
- Department of Urology, University Hospital Bonn (UKB), Bonn, Germany.
- Institute of Experimental Oncology, University Hospital Bonn (UKB), Bonn, Germany.
- Department of Urology and Paediatric Urology, Julius Maximilians University Medical Center of Würzburg, Würzburg, Germany.
- Department of Urology and Paediatric Urology, Saarland University, Homburg, Germany.
Zitieren
APA
Mattigk, A., Cano Garcia, C., Klümper, N., Cox, A., Hahn, O., Junker, K., Erdmann, K., Schmucker, P., Flegar, L., Zengerling, F., Banek, S., Ellinger, J., Buerk, B. T., Huber, J., Kalogirou, C., Zeuschner, P., & Hoeh, B. (2024). Adjuvant Therapy with Pembrolizumab in Renal Cell Carcinoma: Real-World Experiences from a Retrospective, Multi-Institutional Cohort. Urologia Internationalis, 109(3), 291-298. https://doi.org/10.1159/000543278
Vancouver
Mattigk A, Cano Garcia C, Klümper N, Cox A, Hahn O, Junker K, et al. Adjuvant Therapy with Pembrolizumab in Renal Cell Carcinoma: Real-World Experiences from a Retrospective, Multi-Institutional Cohort. Urologia Internationalis. 2024;109(3):291-298. doi:10.1159/000543278
BibTeX
@article{Mattigk2024,
author = {Mattigk, Angelika and Cano Garcia, Cristina and Klümper, Niklas and Cox, Alexander and Hahn, Oliver and Junker, Kerstin and Erdmann, Kati and Schmucker, Philipp and Flegar, Luka and Zengerling, Friedemann and Banek, Severine and Ellinger, Jörg and Buerk, Bjoern Thorben and Huber, Johannes and Kalogirou, Charis and Zeuschner, Philip and Hoeh, Benedikt},
title = {Adjuvant Therapy with Pembrolizumab in Renal Cell Carcinoma: Real-World Experiences from a Retrospective, Multi-Institutional Cohort},
journal = {Urologia Internationalis},
year = {2024},
volume = {109},
number = {3},
pages = {291--298},
doi = {10.1159/000543278}
}
EUVIMED